Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05951959 | A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma(TrAVeRse) | active not recruiting | Phase 2 | 108 | AstraZenecaINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06183489 | Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma(ERASMM) | active not recruiting | Phase 2 | 50 | European Myeloma Network B.V.NETWORK | 4 | Sep 2, 2026 |
| clinicaltrials |
| NCT06762080 | Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis | active not recruiting | Phase 1 / Phase 2 | 36 | Guangzhou Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06809530 | Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis | active not recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02114229 | Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors(SJATRT) | active not recruiting | Phase 2 | 125 | St. Jude Children's Research HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03600701 | Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03801434 | Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | active not recruiting | Phase 2 | 8 | Stanford UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04262843 | Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia | active not recruiting | Phase 2 | 33 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04315324 | Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | active not recruiting | Phase 1 / Phase 2 | 67 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04557956 | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | active not recruiting | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05054439 | A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC | active not recruiting | Phase 2 | 45 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05142241 | Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial | active not recruiting | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05627635 | FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05672316 | Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05945823 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | active not recruiting | Phase 2 | 53 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 1, 2026 | clinicaltrials |
| NCT06390852 | Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) | active not recruiting | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06730750 | A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 360 | Bristol-Myers SquibbINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT02955394 | Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer | active not recruiting | Phase 2 | 61 | University of Colorado, DenverOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT03505320 | A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer(ILUSTRO) | active not recruiting | Phase 2 | 143 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Aug 31, 2026 | clinicaltrials |
| NCT03652428 | Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) | active not recruiting | Phase 1 / Phase 2 | 24 | University of Maryland, BaltimoreOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04006522 | 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma | active not recruiting | Phase 2 | 46 | James BrugarolasOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04145115 | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden | active not recruiting | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 2 | Aug 31, 2026 | clinicaltrials |
| NCT04736173 | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer(ARC-10) | active not recruiting | Phase 2 | 169 | Arcus Biosciences, Inc.INDUSTRY | 10 | Aug 31, 2026 | clinicaltrials |
| NCT04925063 | The Effect of Metformin in Patients With Newly Diagnosed mHSPC | active not recruiting | Phase 2 | 266 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05013450 | Dupilumab_Metastatic NSCLC | active not recruiting | Phase 1 / Phase 2 | 33 | Thomas MarronOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05126719 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 238 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05207670 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies(MorningSun) | active not recruiting | Phase 2 | 320 | Genentech, Inc.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05460273 | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | active not recruiting | Phase 1 / Phase 2 | 119 | AstraZenecaINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT01841736 | Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | active not recruiting | Phase 2 | 171 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT02152995 | Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer | active not recruiting | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02179086 | Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 624 | NRG OncologyOTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT02270814 | Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma(CACTUX) | active not recruiting | Phase 2 | 74 | Washington University School of MedicineOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02311933 | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer | active not recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02339571 | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma | active not recruiting | Phase 2 / Phase 3 | 600 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 / Phase 3 | 444 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT02849496 | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer | active not recruiting | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03371719 | Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial | active not recruiting | Phase 2 | 298 | NRG OncologyOTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03473743 | A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer | active not recruiting | Phase 1 / Phase 2 | 125 | Janssen Research & Development, LLCINDUSTRY | 13 | Aug 28, 2026 | clinicaltrials |
| NCT03595124 | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | active not recruiting | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT04379596 | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)(DG-03) | active not recruiting | Phase 2 | 452 | AstraZenecaINDUSTRY | 14 | Aug 28, 2026 | clinicaltrials |
| NCT04486378 | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | active not recruiting | Phase 2 | 327 | BioNTech SEINDUSTRY | 7 | Aug 28, 2026 | clinicaltrials |
| NCT04802590 | Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 210 | The Lymphoma Academic Research OrganisationOTHER | 3 | Aug 28, 2026 | clinicaltrials |
| NCT05668858 | A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 70 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05949606 | A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 95 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06068985 | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade(CHERRY-PICK) | active not recruiting | Phase 2 | 63 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06428396 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | active not recruiting | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Aug 28, 2026 | clinicaltrials |
| NCT07791602 | Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer(IDEAL-RT) | active not recruiting | Phase 2 | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01064466 | Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 2, 2026source: clinicaltrials